全文获取类型
收费全文 | 207篇 |
免费 | 10篇 |
专业分类
儿科学 | 15篇 |
基础医学 | 25篇 |
口腔科学 | 1篇 |
临床医学 | 17篇 |
内科学 | 67篇 |
皮肤病学 | 13篇 |
神经病学 | 3篇 |
外科学 | 6篇 |
综合类 | 12篇 |
预防医学 | 2篇 |
药学 | 11篇 |
中国医学 | 4篇 |
肿瘤学 | 41篇 |
出版年
2022年 | 6篇 |
2021年 | 5篇 |
2020年 | 8篇 |
2019年 | 8篇 |
2018年 | 5篇 |
2017年 | 9篇 |
2016年 | 7篇 |
2015年 | 5篇 |
2014年 | 10篇 |
2013年 | 21篇 |
2012年 | 5篇 |
2011年 | 6篇 |
2010年 | 8篇 |
2009年 | 11篇 |
2008年 | 5篇 |
2007年 | 6篇 |
2006年 | 7篇 |
2005年 | 7篇 |
2004年 | 6篇 |
2003年 | 7篇 |
2002年 | 5篇 |
2001年 | 8篇 |
2000年 | 4篇 |
1999年 | 5篇 |
1998年 | 1篇 |
1997年 | 6篇 |
1996年 | 5篇 |
1995年 | 4篇 |
1994年 | 2篇 |
1993年 | 1篇 |
1991年 | 2篇 |
1989年 | 1篇 |
1988年 | 2篇 |
1987年 | 2篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1982年 | 2篇 |
1981年 | 3篇 |
1980年 | 3篇 |
1979年 | 5篇 |
1975年 | 1篇 |
排序方式: 共有217条查询结果,搜索用时 46 毫秒
1.
2.
Hydroxyurea is a chemotherapeutic agent used for myeloproliferative disorders and sickle cell anemia that is well known to cause painful mucocutaneous ulcers, typically involving the legs or mouth. However, genital ulcerations due to hydroxyurea therapy are a rare, and likely underrecognized, adverse effect with only a few cases reported in the literature to date. Ulcers of the lower legs caused by hydroxyurea are associated with a diagnostic delay, and this is likely exacerbated in cases of genital ulceration due to a lack of awareness. Herein we present two cases of painful genital ulceration in patients on hydroxyurea therapy. In the first Case, an 87 year-old male with polycythemia vera developed an ulcer on the scrotum, which was assessed initially through virtual visits during the COVID-19 pandemic, and was refractory to topical and oral antibiotic treatments. The second case was a 79 year-old male with essential thrombocythemia and a history of persistent leg ulcers who developed erosions of the glans penis. Both patients experienced complete resolution within weeks of discontinuing hydroxyurea therapy. In conclusion, genital ulcers and erosions induced by hydroxyrea may be underrecognized in clinical practice, but if identified, withdrawal of hydroxyurea leads to quick resolution of these lesions and the associated pain. 相似文献
3.
Sherif M. Badawy Alexis A. Thompson Robert I. Liem 《Hematology/oncology and stem cell therapy》2018,11(3):142-148
Background
Hydroxyurea reduces complications and improves health-related quality of life (HRQOL) in sickle cell disease (SCD) patients, however adherence remains suboptimal. Understanding patients’ views of hydroxyurea is critical to optimize adherence, particularly in adolescents and young adults (AYA). Study objectives were to assess beliefs about hydroxyurea using the Beliefs about Medicines Questionnaire (BMQ), and to examine the relationship of patients’ beliefs to their hydroxyurea adherence and HRQOL.Methods
Thirty-four AYA with SCD participated in a cross-sectional study January–December 2015. Study assessments included BMQ to examine beliefs about hydroxyurea; Visual Analogue Scale (VAS) to assess hydroxyurea adherence; and Patient Reported Outcomes Measurement Information System (PROMIS®) to evaluate HRQOL.Results
Participants (41% female, 91% Black) had median age of 13.5 (IQR 12–18) years. Participants’ concerns about overuse of medications correlated with concerns about hydroxyurea (rs?=?0.36, p?=?0.04) and overall harm of medications (rs?=?0.5, p?=?0.003). Participants’ age positively correlated with the necessity of hydroxyurea (rs?=?0.45, p?=?0.007). Participants’ concerns about hydroxyurea and overuse of medications positively correlated with anxiety (rs?=?0.41, p?=?0.02; rs?=?0.44, p?=?0.01) and depression (rs?=?0.37, p?=?0.04; rs?=?0.54, p?=?0.001), but inversely correlated with peer relationships (rs?=??0.45, p?=?0.03; rs?=??0.44, p?=?0.03), respectively, suggesting better HRQOL with concerns. Fifty percent of participants reported low hydroxyurea adherence (VAS?<?80%), which was more seen in patients with higher concerns about hydroxyurea (p?=?0.02).Conclusions
Beliefs about hydroxyurea correlated with HRQOL scores and adherence levels. Addressing patients’ concern about hydroxyurea and medications overall as well as routine assessment of adherence and beliefs could help to overcome adherence barriers. 相似文献4.
Olinda Maria Rodrigues de Araujo Maria Lúcia Ivo Marcos Antonio Ferreira Júnior Elenir Rose Jardim Cury Pontes Ieda Maria Gon?alves Pacce Bispo Eveny Cristine Luna de Oliveira 《Revista latino-americana de enfermagem》2015,23(1):67-73
OBJECTIVE:
to estimate survival, mortality and cause of death among users or not of hydroxyurea with sickle cell disease.METHOD:
cohort study with retrospective data collection, from 1980 to 2010 of patients receiving inpatient treatment in two Brazilian public hospitals. The survival probability was determined using the Kaplan-Meier estimator, survival calculations (SPSS version 10.0), comparison between survival curves, using the log rank method. The level of significance was p=0.05.RESULTS:
of 63 patients, 87% had sickle cell anemia, with 39 using hydroxyurea, with a mean time of use of the drug of 20.0±10.0 years and a mean dose of 17.37±5.4 to 20.94±7.2 mg/kg/day, raising the fetal hemoglobin. In the comparison between those using hydroxyurea and those not, the survival curve was greater among the users (p=0.014). A total of 10 deaths occurred, with a mean age of 28.1 years old, and with Acute Respiratory Failure as the main cause.CONCLUSION:
the survival curve is greater among the users of hydroxyurea. The results indicate the importance of the nurse incorporating therapeutic advances of hydroxyurea in her care actions. 相似文献5.
E.?LengfelderEmail author U.?Berger A.?Reiter A.?Hochhaus R.?Hehlmann 《Der Internist》2003,44(8):1011-1030
Zusammenfassung Die chronischen myeloproliferativen Erkrankungen (CMPE) sind neoplastische Erkrankungen der hämatopoetischen Stammzelle. Sie umfassen die chronische myeloische Leukämie (CML), die Polycythaemia vera, die essentielle Thrombozythämie, die primäre Osteomyelofibrose und Übergangsformen innerhalb dieser Erkrankungen sowie zwischen den CMPE und den Myelodysplasien. Hauptziele der Initialdiagnostik sind die genaue Klassifizierung der Erkrankung, die Erfassung von Risiko- und Prognosefaktoren sowie die Charakterisierung des malignen Klons mittels Zytogenetik und molekulargenetischer Methoden. Herkömmliche Therapeutika für alle CMPE sind Hydroxyurea und Interferon-. Bei der CML führt die gezielte Hemmung der BCR-ABL-Tyrosinkinase mit Imatinib klinisch zu hohen Ansprechraten. Die bisher einzige kurative Therapie für alle Entitäten ist die allogene Stammzelltransplantation. Bei der CML sollte die Indikation auf der Basis der neueren Risikoscores gestellt werden. Bei den BCR-ABL-negativen CMPE ist sie nur bei ungünstigem Krankheitsverlauf in Erwägung zu ziehen.
相似文献
相似文献
6.
7.
Kenichi Nomura Mitsushige Nakao Yosuke Matsumoto Sawako Taji Naohisa Yoshida Shoji Mitsufuji 《Hematology (Amsterdam, Netherlands)》2013,18(2):131-133
We describe a patient with chronic myelogenous leukemia who developing severe intestinal bleeding after allogeneic peripheral blood stem cells transplantation (allo-PBSCT). PBSC were obtained from an HLA one-locus mismatch sibling donor. On day 26 after PBSCT, although there was no sign of graft-versus-host disease (GVHD) in either the skin or the liver, diarrhea and severe intestinal bleeding occurred. The histopathological examination of the colon revealed complete denudation of the epithelial cells of the mucosa and no obvious apoptosis. Neither red cell fragments nor hemorrhagic diathesis was seen during this episode and the patient was diagnosed as having GVHD. Methylpredonisolone followed by FK506 may be effective in controlling intestinal bleeding and was used in our patient. Acute GVHD involving only the intestine has rarely been described but when using HLA-mismatched PBSCs, acute GVHD may occur severely and atypically. 相似文献
8.
M M Hreshchyshyn B S Aron R C Boronow E W Franklin H M Shingleton J A Blessing 《International journal of radiation oncology, biology, physics》1979,5(3):317-322
In a prospective study by the Gynecologic Oncology Group (GOG), 104 evaluable patients with cervical squamous cell carcinoma Stages IIIB and IVA were randomly assigned to treatment with hydroxyurea or placebo in combination with radiation. There were no deaths resulting from the treatment. Hematologic toxicity was more common and more severe in patients who received hydroxyurea. Response was evaluated in terms of complete tumor regression, duration of progression-free interval and survival probability. By all those parameters the response was significantly better in the groups of patients receiving hydroxyurea. 相似文献
9.
Wang WC Morales KH Scher CD Styles L Olivieri N Adams R Brambilla D;STOP Investigators 《The Journal of pediatrics》2005,147(2):244-247
OBJECTIVE: To determine whether long-term transfusion improves growth in children with sickle cell anemia. STUDY DESIGN: In the Stroke Prevention Trial for Sickle Cell Anemia Study, patients were randomized to receive long-term transfusion (CTX) or standard care (STC). Transfusions were administered every 3 to 5 weeks, and hemoglobin S levels were maintained at 30% pretransfusion for an average of 2 years. Serial height and weight measurements (obtained every 3 months), body mass index (BMI) values, and growth z-scores were analyzed. RESULTS: Children in the CTX (n=53) and STC (n=41) groups were similar at baseline. After 24 months, the z-scores for height, weight, and BMI of those receiving CTX had improved significantly, whereas no changes occurred in the STC group. Patients in the CTX group approached normal height-for-age and weight-for-age z-scores. Patients from a large historical control group had significantly lower weight and height growth velocities than patients in the CTX group. CONCLUSIONS: Patients in the Stroke Prevention Trial for Sickle Cell Anemia Study who received CTX had improved height and weight and BMI over a 2-year period. Higher hemoglobin levels resulting from transfusion may improve growth by lowering energy expenditure. In addition to the prevention of vasoocclusive events, CTX results in significant improvement in the growth of children with sickle cell disease. 相似文献
10.
Hydroxyurea (HU) has been shown to reduce the frequency of vaso-occlusive manifestations in both adults and children with sickle cell disease (SCD), and the induction of hemoglobin F (HbF) is thought to be the underlying mechanism responsible for clinical improvement in some patients. However, there exists no good correlation between the amount of HbF increase and clinical response. Recent studies suggest that increased activity of the coagulation system may be important in the pathogenesis of vascular occlusion in sickle cell disease. To analyze the effect of HU on the coagulation system in children, the authors studied the levels of some coagulation factors and natural inhibitors. Eleven children who had been treated with HU because of SCD (5 patients), sickle- β-thalassemia (3 patients), and β-thalassemia intermedia (3 patients) were enrolled in the study. Levels of the coagulation factors II, V, VII, VIII, IX, X, XI, and XII, and of protein C and protein S, prothrombin times, activated partial thromboplastine times, thrombin times, and reptilase times were measured before the treatment and at the 5th or 6th months of HU therapy when the patients were in a steady-state condition. There was a decrease in all of the coagulation factors except for FIX and FXII and in inhibitors such as protein C and protein S. However, statistically significant decreases were observed only in factor VIII and protein C levels. The rates of decrease were 54.8 and 12.5% ( p = .015 and p = .018) in FVIII and protein C, respectively. This result shows that HU has significant effects on the coagulation and natural inhibitory systems. 相似文献